Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.65 |
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | PNP | P00491 | 2/20 | 0.59 |
| ▸ | KRAS | P01116 | 2/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549083 | 1.00 | HINT1 (0.65) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL1164486 | 0.99 | HINT1 (0.64) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL14957138 | 0.99 | HINT1 (0.64) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| Guanosine SCHEMBL11986902 | 0.90 | HPGD (0.76) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| Guanosine SCHEMBL24049416 | 0.90 | HPGD (0.76) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| Guanosine SCHEMBL24049608 | 0.90 | HPGD (0.76) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| Guanosine SCHEMBL24049467 | 0.90 | HPGD (0.76) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| Guanosine SCHEMBL20750695 | 0.90 | HPGD (0.76) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| Guanosine SCHEMBL8593215 | 0.90 | HPGD (0.76) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| Guanosine SCHEMBL413586 | 0.90 | HPGD (0.76) | HINT1NT5EHPGDGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-9249473-B2 | Compositions and methods for the identification of inhibitors of retroviral infection | Trana Discover, Inc. (US) | 2016-02-02 | — | — | US | claimed |
| US-20140121124-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | GUENTHER RICHARD H (US) | 2014-05-01 | — | — | US | claimed |
| EP-2201118-B1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2012-04-18 | — | — | EP | claimed |
| US-20100291032-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2010-11-18 | — | — | US | claimed |
| EP-2201118-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | Trana Discovery (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009036299-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2009-03-19 | — | — | WO | claimed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024148237-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC INHIBITORS OF MYCOBACTERIA, INCLUDING M. TUBERCULOSIS | TRANA DISCOVERY, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| EP-2201118-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | Trana Discovery (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-2197455-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | North Carolina State University (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2010036795-A2 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009038666-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009036299-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291032-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRMT1L, TRMT1, TARBP1 | HINT1 891/4885NT5E 406/4885HPGD 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.